Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

S0833, Modified Total Therapy 3 (TT3) for Newly Diagnosed Patients With Multiple Myeloma (MM): A Phase II SWOG Trial for Patients Aged ≤ 65 Years

NCT01055301 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT01055301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01055301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
S0833, Modified Total Therapy 3 (TT3) for Newly Diagnosed Patients With Multiple Myeloma (MM): A Phase II SWOG Trial for Patients Aged ≤ 65 Years
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Withdrawn
Start date
July 31, 2011
Completion date
July 31, 2011
Enrollment
0 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, plasma cell myeloma